Additionally, it is used as monotherapy for first-line treatment of adult patients with metastatic NSCLC whose tumors have a PD-L1 expression in ≥ 50% tumor cells or ≥ 10% tumor-infiltrating immune cells and lacks EGFR or ALK genomic tumor aberrations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.